Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results
Open Access
- 1 April 1999
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 10 (4) , 403-411
- https://doi.org/10.1023/a:1008360406322
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Global cancer statisticsCA: A Cancer Journal for Clinicians, 1999
- Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.Journal of Clinical Oncology, 1997
- Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxicAnnals of Oncology, 1996
- Assessment of Anthracycline Cardiomyopathy by Endomyocardial BiopsyUltrastructural Pathology, 1994
- Taxol in combination with doxorubicin or etoposide possible antagonism in vitroCancer, 1993
- Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast CancerJNCI Journal of the National Cancer Institute, 1991
- Comprehensive Criteria for Assessing Therapy-Induced ToxicityCancer Investigation, 1989
- Complete Remissions in Metastatic Breast Cancer Treated with Combination Drug TherapyAnnals of Internal Medicine, 1979
- Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramideJournal of Chronic Diseases, 1960
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958